Abstract
Delivering a drug to a specific target in the body is comparable to the “magic bullet principle” applied in Nuclear Medicine. If clinical medicine today found treatment options by targeting specific receptors, proteins or enzymes by “small-molecule drugs” it utilizes concepts that have been initially described by Nobel Laureate George von Hevesy as “tracer principle”. This article is going to show that molecular imaging probes in Nuclear Medicine can be regarded as proof of principle of many of recent trends in diagnosis and therapy and offers exciting opportunities for further developments. Radioiodine therapy of benign and malignant thyroid disease has been established in Nuclear Medicine over six decades ago and is a fine example for using the same highly specific probe for diagnosis and treatment of a given disease. The use of radio labeled monoclonal antibodies against surface receptors of tumor cells (e.g. CEA) dominated diagnostic Nuclear Medicine in the eighties and sees a recent revival in lymphoma treatment radioimmunotherapy. Finally Nuclear Medicine has shown that it may advance drug development by visualizing its biodistribution and site of action. On the other hand some drugs like somatostatin analogues have been reinvented as diagnostic and therapeutic probes over a decade after their initial introduction as therapeutics. Molecular Imaging and targeted therapy are merging and potentate their individual strength. Nuclear Medicine has ample experience in applying Molecular Imaging in clinical research and practice and has a bright future in this exciting field.
Keywords: Targeted therapy, nuclear medicine, tracer principle, molecular imaging, magic bullet, P4 medicine
Current Pharmaceutical Design
Title: Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Volume: 15 Issue: 2
Author(s): Thomas Leitha
Affiliation:
Keywords: Targeted therapy, nuclear medicine, tracer principle, molecular imaging, magic bullet, P4 medicine
Abstract: Delivering a drug to a specific target in the body is comparable to the “magic bullet principle” applied in Nuclear Medicine. If clinical medicine today found treatment options by targeting specific receptors, proteins or enzymes by “small-molecule drugs” it utilizes concepts that have been initially described by Nobel Laureate George von Hevesy as “tracer principle”. This article is going to show that molecular imaging probes in Nuclear Medicine can be regarded as proof of principle of many of recent trends in diagnosis and therapy and offers exciting opportunities for further developments. Radioiodine therapy of benign and malignant thyroid disease has been established in Nuclear Medicine over six decades ago and is a fine example for using the same highly specific probe for diagnosis and treatment of a given disease. The use of radio labeled monoclonal antibodies against surface receptors of tumor cells (e.g. CEA) dominated diagnostic Nuclear Medicine in the eighties and sees a recent revival in lymphoma treatment radioimmunotherapy. Finally Nuclear Medicine has shown that it may advance drug development by visualizing its biodistribution and site of action. On the other hand some drugs like somatostatin analogues have been reinvented as diagnostic and therapeutic probes over a decade after their initial introduction as therapeutics. Molecular Imaging and targeted therapy are merging and potentate their individual strength. Nuclear Medicine has ample experience in applying Molecular Imaging in clinical research and practice and has a bright future in this exciting field.
Export Options
About this article
Cite this article as:
Leitha Thomas, Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy, Current Pharmaceutical Design 2009; 15 (2) . https://dx.doi.org/10.2174/138161209787002898
DOI https://dx.doi.org/10.2174/138161209787002898 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology A Long Time History of a Mediastinal Fibrosis with Triple Vascular Stenosis
Current Respiratory Medicine Reviews Therapeutic Antibodies
Drug Design Reviews - Online (Discontinued) Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Recent Patents of Gene Mutation Relative to JAK/STAT Pathway and Their Implication in Myeloproliferative Diseases
Recent Patents on DNA & Gene Sequences Benzisothiazolone Derivatives Exhibit Cytotoxicity in Hodgkin’s Lymphoma Cells through NF-κB Inhibition and are Synergistic with Doxorubicin and Etoposide
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Current Cancer Drug Targets NK Cell Receptors and Their Interactions with MHC
Current Pharmaceutical Design Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design CFTR and MDR: ABC Transporters with Homologous Structure but Divergent Function
Current Genomics New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry False Positive of <sup>68</sup>Ga-DOTATATE PET-CT in a Paraganglioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Psoriatic Arthritis – Review of the Immunologic, Clinic and Therapeutic Aspects of an Inflammatory Systemic Disease
Current Rheumatology Reviews Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design